Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Direxion Daily FTSE China Bull 3x Shares trades at $29.28. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| VRTX | YINN | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $529.65 | $56.62 |
52-Week Low | $376.62 | $21.45 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $31.50, up 1.68% with a bullish technical signal. The ETF tracks Chinese equities, showing strength amid Hang Seng Index outperformance versus Asian peers. Moving averages signal bullish momentum while oscillators remain neutral. Recent news highlights China's AI investment plans and export growth, though regulatory tensions with the US persist.
Outlook remains cautiously optimistic given China's tech focus and infrastructure spending, but leveraged structure amplifies risks. Key risks include US-China trade tensions and China's economic stabilization efforts. Investors should weigh the ETF's 3x leverage against China's growth trajectory and regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
